FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169030260> ?p ?o ?g. }

• W2169030260 endingPage "e64073" @default.
• W2169030260 startingPage "e64073" @default.
• W2169030260 abstract "Background Up to now a malaria vaccine remains elusive. The Plasmodium falciparum serine repeat antigen-5 formulated with aluminum hydroxyl gel (BK-SE36) is a blood-stage malaria vaccine candidate that has undergone phase 1a trial in malaria-naive Japanese adults. We have now assessed the safety and immunogenicity of BK-SE36 in a malaria endemic area in Northern Uganda. Methods We performed a two-stage, randomized, single-blinded, placebo-controlled phase 1b trial (Current Controlled trials ISRCTN71619711). A computer-generated sequence randomized healthy subjects for 2 subcutaneous injections at 21-day intervals in Stage1 (21–40 year-olds) to 1-mL BK-SE36 (BKSE1.0) (n = 36) or saline (n = 20) and in Stage2 (6–20 year-olds) to BKSE1.0 (n = 33), 0.5-mL BK-SE36 (BKSE0.5) (n = 33), or saline (n = 18). Subjects and laboratory personnel were blinded. Safety and antibody responses 21-days post-second vaccination (Day42) were assessed. Post-trial, to compare the risk of malaria episodes 130–365 days post-second vaccination, Stage2 subjects were age-matched to 50 control individuals. Results Nearly all subjects who received BK-SE36 had induration (Stage1, n = 33, 92%; Stage2, n = 63, 96%) as a local adverse event. No serious adverse event related to BK-SE36 was reported. Pre-existing anti-SE36 antibody titers negatively correlated with vaccination-induced antibody response. At Day42, change in antibody titers was significant for seronegative adults (1.95-fold higher than baseline [95% CI, 1.56–2.43], p = 0.004) and 6–10 year-olds (5.71-fold [95% CI, 2.38–13.72], p = 0.002) vaccinated with BKSE1.0. Immunogenicity response to BKSE0.5 was low and not significant (1.55-fold [95% CI, 1.24–1.94], p = 0.75). In the ancillary analysis, cumulative incidence of first malaria episodes with ≥5000 parasites/µL was 7 cases/33 subjects in BKSE1.0 and 10 cases/33 subjects in BKSE0.5 vs. 29 cases/66 subjects in the control group. Risk ratio for BKSE1.0 was 0.48 (95% CI, 0.24–0.98; p = 0.04). Conclusion BK-SE36 is safe and immunogenic. The promising potential of BK-SE36, observed in the follow-up study, warrants a double-blind phase 1/2b trial in children under 5 years. Trial Registration Controlled-Trials.com ISRCTN71619711 ISRCTN71619711" @default.
• W2169030260 created "2016-06-24" @default.
• W2169030260 creator A5000373863 @default.
• W2169030260 creator A5002550974 @default.
• W2169030260 creator A5004809977 @default.
• W2169030260 creator A5016169856 @default.
• W2169030260 creator A5016180390 @default.
• W2169030260 creator A5016846269 @default.
• W2169030260 creator A5020676620 @default.
• W2169030260 creator A5022217516 @default.
• W2169030260 creator A5023267458 @default.
• W2169030260 creator A5026266245 @default.
• W2169030260 creator A5028701161 @default.
• W2169030260 creator A5031756748 @default.
• W2169030260 creator A5034371042 @default.
• W2169030260 creator A5042229974 @default.
• W2169030260 creator A5047154688 @default.
• W2169030260 creator A5063767722 @default.
• W2169030260 creator A5067265605 @default.
• W2169030260 creator A5081815480 @default.
• W2169030260 creator A5085519388 @default.
• W2169030260 creator A5086728803 @default.
• W2169030260 creator A5090656487 @default.
• W2169030260 date "2013-05-28" @default.
• W2169030260 modified "2023-10-01" @default.
• W2169030260 title "Phase 1b Randomized Trial and Follow-Up Study in Uganda of the Blood-Stage Malaria Vaccine Candidate BK-SE36" @default.
• W2169030260 cites W1501895899 @default.
• W2169030260 cites W1527871699 @default.
• W2169030260 cites W1554592575 @default.
• W2169030260 cites W1964273312 @default.
• W2169030260 cites W1964366824 @default.
• W2169030260 cites W1973827427 @default.
• W2169030260 cites W1998968974 @default.
• W2169030260 cites W2000369867 @default.
• W2169030260 cites W2002836781 @default.
• W2169030260 cites W2004896101 @default.
• W2169030260 cites W2021926390 @default.
• W2169030260 cites W2034720263 @default.
• W2169030260 cites W2039502197 @default.
• W2169030260 cites W2051441019 @default.
• W2169030260 cites W2053614206 @default.
• W2169030260 cites W2086732127 @default.
• W2169030260 cites W2087490172 @default.
• W2169030260 cites W2091844045 @default.
• W2169030260 cites W2095554063 @default.
• W2169030260 cites W2108476551 @default.
• W2169030260 cites W2113442583 @default.
• W2169030260 cites W2124563608 @default.
• W2169030260 cites W2131277865 @default.
• W2169030260 cites W2131311918 @default.
• W2169030260 cites W2133572764 @default.
• W2169030260 cites W2138971282 @default.
• W2169030260 cites W2142655452 @default.
• W2169030260 cites W2145891164 @default.
• W2169030260 cites W2244674613 @default.
• W2169030260 doi "https://doi.org/10.1371/journal.pone.0064073" @default.
• W2169030260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3665850" @default.
• W2169030260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23724021" @default.
• W2169030260 hasPublicationYear "2013" @default.
• W2169030260 type Work @default.
• W2169030260 sameAs 2169030260 @default.
• W2169030260 citedByCount "57" @default.
• W2169030260 countsByYear W21690302602013 @default.
• W2169030260 countsByYear W21690302602014 @default.
• W2169030260 countsByYear W21690302602015 @default.
• W2169030260 countsByYear W21690302602016 @default.
• W2169030260 countsByYear W21690302602017 @default.
• W2169030260 countsByYear W21690302602018 @default.
• W2169030260 countsByYear W21690302602019 @default.
• W2169030260 countsByYear W21690302602020 @default.
• W2169030260 countsByYear W21690302602021 @default.
• W2169030260 countsByYear W21690302602022 @default.
• W2169030260 countsByYear W21690302602023 @default.
• W2169030260 crossrefType "journal-article" @default.
• W2169030260 hasAuthorship W2169030260A5000373863 @default.
• W2169030260 hasAuthorship W2169030260A5002550974 @default.
• W2169030260 hasAuthorship W2169030260A5004809977 @default.
• W2169030260 hasAuthorship W2169030260A5016169856 @default.
• W2169030260 hasAuthorship W2169030260A5016180390 @default.
• W2169030260 hasAuthorship W2169030260A5016846269 @default.
• W2169030260 hasAuthorship W2169030260A5020676620 @default.
• W2169030260 hasAuthorship W2169030260A5022217516 @default.
• W2169030260 hasAuthorship W2169030260A5023267458 @default.
• W2169030260 hasAuthorship W2169030260A5026266245 @default.
• W2169030260 hasAuthorship W2169030260A5028701161 @default.
• W2169030260 hasAuthorship W2169030260A5031756748 @default.
• W2169030260 hasAuthorship W2169030260A5034371042 @default.
• W2169030260 hasAuthorship W2169030260A5042229974 @default.
• W2169030260 hasAuthorship W2169030260A5047154688 @default.
• W2169030260 hasAuthorship W2169030260A5063767722 @default.
• W2169030260 hasAuthorship W2169030260A5067265605 @default.
• W2169030260 hasAuthorship W2169030260A5081815480 @default.
• W2169030260 hasAuthorship W2169030260A5085519388 @default.
• W2169030260 hasAuthorship W2169030260A5086728803 @default.
• W2169030260 hasAuthorship W2169030260A5090656487 @default.
• W2169030260 hasBestOaLocation W21690302601 @default.
• W2169030260 hasConcept C126322002 @default.
• W2169030260 hasConcept C142724271 @default.

• next